Level 3 · Human studyClinical trial

L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults

Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, Trimarco V, Frullone S, Santulli G

Frontiers in cardiovascular medicine · 12 April 2022

AUTHORS’ ABSTRACT

Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells. In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults.

Clinical trial registration : www.ClinicalTrials.gov, identifier: NCT04962841.

Original abstract, reproduced without modification. © The authors, distributed under a Creative Commons CC BY licence. The exact terms are given in the original article.

Scientific information content; it does not replace the advice of a healthcare professional. The presence of a study in this library does not constitute a claim about our products.

← All studies